Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use

Next Previous
Search
Trial Profile

Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narsoplimab (Primary)
  • Indications Thrombotic microangiopathy
  • Focus Adverse reactions; Expanded access; Therapeutic Use

    • Most Recent Events

    • 20 Feb 2025 According to an Omeros Corporation media release,These results complete the set of independently conducted analyses for inclusion in the narsoplimab BLA resubmission to FDA planned for later this quarter and in the MAA submission to European regulators targeted by mid-year.
    • 20 Feb 2025 Results of statistical analyses of survival in narsoplimab-treated expanded access program presented in the Omeros Corporation media release.
    • 11 Feb 2025 According to an Omeros Corporation media release, data from this trial will be presented at the 2025 Tandem Meetings ,the Transplantation and Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolulu, Hawaii.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top